<DOC>
	<DOCNO>NCT00662779</DOCNO>
	<brief_summary>It primary hypothesis pretreatment arformoterol provide superior protection EIB child mild-moderate asthma compare placebo add current asthma regimen . Our secondary hypothesis nebulized arformoterol comparable protection EIB compare inhale formoterol dry powder inhaler .</brief_summary>
	<brief_title>Bronchoprotective Effect Arformoterol Children With Exercise-Induced Bronchospasm ( EIB )</brief_title>
	<detailed_description>This study randomize , double-blind , double-dummy , crossover clinical trial consist 5 study visit last 3 week . Fifteen child 12-17 year age asthma EIB , regardless current asthma therapy eligible trial .</detailed_description>
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Asthma , Exercise-Induced</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Children 1217 year age Physician diagnose asthma least 6 month Long term controller medication least 4 week use Females childbearing potential agree use acceptable form birth control duration study EIB diagnose positive exercise challenge screen Forced expiratory volume 1 second ( FEV1 ) great 70 % predict screening visit History cardiac dysfunction Inability perform exercise challenge ( i.e. , run treadmill perform adequate spirometry ) Upper respiratory infection last 4 week Severe exacerbation , use oral steroid , hospitalization last 3 month Chronic ( great 2 week ) use Long Acting Beta Agonist ( LABA ) Pregnancy lactation History paradoxical bronchospasm betaagonist Obesity define BMI great 30 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>asthma</keyword>
	<keyword>exercise induce bronchospasm</keyword>
	<keyword>prevention</keyword>
	<keyword>EIB</keyword>
	<keyword>child</keyword>
</DOC>